| factor xii deficiency | A deficiency of a specific blood clotting factor (XII) that may be genetic or acquired. Administration of heparin or severe liver disease may result in factor XII (Hageman factor) deficiency. There are usually no symptoms associated with this deficiency, but there may be symptoms of mild blood loss in some cases. Treatment is generally unnecessary. Individuals should be cautioned against the use of medications (for example aspirin, warfarin, heparin) with anticoagulant activity, due to risk of exaggerated effects. (27 Sep 1997) |
|---|---|
| factor xiia | <enzyme> Activated form of factor xii. In the initial event in the intrinsic pathway of blood coagulation, kallikrein (with cofactor high molecular weight kininogen) cleaves factor xii to xiia. Factor xiia is then further cleaved by kallikrein, plasmin, and trypsin to yield smaller factor xii fragments (hageman-factor fragments). These fragments increase the activity of prekallikrein to kallikrein but decrease the procoagulant activity of factor xii. Registry number: EC 3.4.21.38 (12 Dec 1998) |
| factor xiii | <chemical> Fibrin stabilizing factor. It is a glycoprotein activated by thrombin in the presence of calcium to form factor xiiia. Factor xiii is found evenly distributed between plasma and platelets. Its function is to stabilise the formation of the fibrin polymer (clot) which culminates the coagulation cascade. Chemical name: Blood-coagulation factor XIII (12 Dec 1998) |
| factor xiii deficiency | A deficiency of blood coagulation factor xiii or fibrin stabilizing factor (fsf) which enables fibrin to form a firm blood clot. Deficiency of this factor produces a clinical haemorrhagic diathesis. (12 Dec 1998) |
| factor, rheumatoid | Rheumatoid factor is an antibody that is measurable in the blood. It is commonly used as a blood test for the diagnosis of rheumatoid arthritis. Rheumatoid factor is present in about 80% of adults (but a much lower proportion of children) with rheumatoid arthritis. It is also present in patients with other connective tissue diseases (such as systemic lupus erythematosus) and in some with infectious diseases (such as infectious hepatitis). (12 Dec 1998) |
| factoress | A factor who is a woman. Source: Websters Dictionary (01 Mar 1998) |
| factorial | 1. Of or pertaining to a factory. 2. <mathematics> Related to factorials. <mathematics> A name given to the factors of a continued product when the former are derivable from one and the same function F(x) by successively imparting a constant increment or decrement h to the independent variable. Thus the product F(x).F(x + h).F(x + 2h) . . . F[x + (n-1)h] is called a factorial term, and its several factors take the name of factorials. The product of the consecutive numbers from unity up to any given number. Source: Websters Dictionary (01 Mar 1998) |
| factorial experiments | An experimental design in which two or more series of treatments are tried in all combinations. (05 Mar 2000) |
| factoring | <mathematics> The act of resolving into factors. Source: Websters Dictionary (01 Mar 1998) |
| Factors I XII | <haematology> Blood clotting factors, especially from humans. These factors form a cascade in which the activation of the first factor leads to enzymic attack on the next factor and so on, finally resulting in blood clotting. (18 Nov 1997) |
| factory | Origin: Cf. F. Factorerie. 1. A house or place where factors, or commercial agents, reside, to transact business for their employers. "The Company's factory at Madras." 2. The body of factors in any place; as, a chaplain to a British factory. 3. A building, or collection of buildings, appropriated to the manufacture of goods; the place where workmen are employed in fabricating goods, wares, or utensils; a manufactory; as, a cotton factory. <medicine> Factory leg, a variety of bandy leg, associated with partial dislocation of the tibia, produced in young children by working in factories. Source: Websters Dictionary (01 Mar 1998) |
| macrophage inhibition factor | <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion. (18 Nov 1997) |
|---|---|
| radiation weighting factor | In radiation protection, a factor weighting the absorbed dose of radiation of a specific type and energy for its effect on tissue. See: equivalent dose. (05 Mar 2000) |
| maise factor | <molecular biology, plant biology> A naturally occurring cytokinin, originally isolated from maize seeds. Its riboside is also a cytokinin. (18 Nov 1997) |
| vascular endothelial growth factor | A growth factor that is responsible for the growth of blood vessels. (12 Dec 1998) |
| mammotropic factor | <protein> Pituitary lactogenic hormone (23 kD) Synthesised on endoplasmic reticulum bound ribosomes as preprolactin that has an N terminal signal peptide that is cleaved from the mature form. The conversion of preprolactin to prolactin has been much used as an assay for membrane insertion. (18 Nov 1997) |
| receptors, atrial natriuretic factor | Cell surface proteins that bind atrial natriuretic factor with high affinity and trigger intracellular changes influencing the behaviour of cells. (12 Dec 1998) |
| receptors, colony-stimulating factor | Cell surface receptors for colony-stimulating factors, local mediators, and hormones that regulate the survival, proliferation, and differentiation of haemopoietic cells. (12 Dec 1998) |
| receptors, epidermal growth factor-urogastrone | Glycoproteins of about 170 kD that have protein kinase activity and span the plasma membranes of growing cells, including tumours. They are activated by the binding of epidermal growth factor-urogastrone which then initiates DNA and protein synthesis. They are not found on mitotically quiescent cells except in the stomach where they control the synthesis and release of digestive enzymes and gastric acid. Transforming growth factor alpha also binds to and activates these receptors. (12 Dec 1998) |
| receptors, fibroblast growth factor | Specific molecular sites or structures on cell membranes that react with fibroblast growth factors (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity. (12 Dec 1998) |
| receptors, granulocyte-colony-stimulating factor | Receptors that bind and internalise granulocyte-colony-stimulating factor. Their mw is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells. (12 Dec 1998) |
| receptors, granulocyte-macrophage colony-stimulating factor | Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. (12 Dec 1998) |
| receptors, growth factor | Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |
| receptors, macrophage colony-stimulating factor | Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response. (12 Dec 1998) |